HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; A 5 year randomized trial

  • Komulainen M
  • Kröger H
  • Tuppurainen M
 et al. 
  • 37

    Readers

    Mendeley users who have this article in their library.
  • 184

    Citations

    Citations of this article.

Abstract

Objectives: We investigated the incidence of new non-vertebral fractures during HRT or low-dose vitamin (Vit) D3supplementation in a 5-year prospective trial. Methods: A total of 464 early postmenopausal women, (a subgroup of the Kuopio Osteoporosis Study, n=13100) were randomized to four groups: (1) HRT, a sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate; (2) Vit D (300 IU/day and 100 IU/day during the fifth year); (3) HRT+Vit D; and (4) placebo. Lumbar (L2-4) and femoral neck bone mineral densities (BMD) were determined by dual X-ray absorptiometry (DXA) at baseline, after 2.5 and 5 years of treatment. All new symptomatic non-vertebral, radiographically defined fractures were recorded. Results: Altogether, 368 women (79%) completed the 5 year treatment. In all, 32 women had 39 non-vertebral fractures during a mean of 4.3 year follow-up (HRT 4, Vit D 10, HRT+Vit D 8 and placebo 17). The reduction in the incidence of new non-verterbral fractures was significant in women with HRT alone (P=0.032) when adjusted by baseline BMD and previous fractures; observed also with the intention-to-treat principle (P=0.048). When the HRT groups were pooled, HRT showed a significantly lower incidence of new non-vertebral fractures (P=0.042) than women receiving placebo and also after adjusting as above (P=0.016); both in valid-case and in the intention-to-treat analysis. In the Vit D group, the fracture incidence was non-significantly decreased (P=0.229) in comparison with the placebo group. The estimated risk of new non-vertebral fractures among women treated with HRT alone was 0.29 (95% CI, 0.10-0.90) and with Vit D 0.47 (95% CI, 0.20-1.14) and with HRT+Vit D 0.44 (95% CI, 0.17-1.15), in comparison with the placebo group (adjusted by femoral BMD and previous fractures). Conclusions: This study is the first prospective trial confirming the beneficial effect of HRT on prevention of peripheral fractures in non-osteoporotic postmenopausal women. The effect of low-dose Vit D remains to be proved. Copyright (C) 1998 Elsevier Science Ireland Ltd.

Author-supplied keywords

  • Fracture risk
  • Hormone replacement therapy
  • Menopause
  • Osteoporosis
  • Vitamin D3

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Marja H. Komulainen

  • Heikki Kröger

  • Marjo T. Tuppurainen

  • Anna Mari Heikkinen

  • Esko Alhava

  • Risto Honkanen

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free